Amgen and Allergan announced their biosimilar candidate ABP 215 “met its primary and secondary endpoints” in a Phase 3 study by demonstrating “clinical equivalence in efficacy, and comparable safety and immunogenicity, to bevacizumab.” ABP 215 is a biosimilar of Avastin (bevacizumab), a recombinant immunoglobulin G1 monoclonal antibody, for treatment of non-squamous non-small cell lung cancer in adults. This is one of four collaborations between Amgen and Allergan on oncology-related biosimilars.
Read the full press release from Amgen and Allergan here.